Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Chemotherapy
12 evidence topics · 13 sources
Chemotherapy recommendations in third-line treatment and beyond: ESMO 2026 guideline
Single-agent chemotherapy for endocrine-pretreated disease: ASCO 2021 guideline
“Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: capecitabine
Comparator regulatory information: eribulin
Comparator regulatory information: paclitaxel protein-bound
Eribulin versus treatment of physician's choice: EMBRACE
“762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival was significantly improved in women assigned to eribulin (median 13·1 months, 95% CI 11·8-14·3) compared with TPC (10·6 months, 9·3-12·5; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·041).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Eribulin versus capecitabine: Study 301
“Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Objective response rates were 11.0% for eribulin and 11.5% for capecitabine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eribulin in hormone receptor-positive disease: pooled analysis of two phase 3 trials
Chemotherapy compared with endocrine-based therapy: network meta-analysis
“We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No chemotherapy or hormone therapy regimen was significantly better than palbociclib plus letrozole for progression-free survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Single-agent chemotherapy in the control arm of a contemporary trial: TROPION-Breast01
Chemotherapy after first-line CDK4/6 inhibitor in practice: systematic review of real-world evidence
Chemotherapy use and outcomes in second and third lines: SOLTI-1801 CDK-PREDICT
“In the second-line setting (n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Targeted agents were frequent in 2L (51%) and capecitabine in 3L (36%), while endocrine monotherapy yielded poorest rwPFS.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote